Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4711 | risankizumab SC Wiki | 1.00 |
| drug4654 | placebo for risankizumab Wiki | 0.67 |
| drug4423 | chlorine dioxide 3000 ppm Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003424 | Crohn Disease NIH | 0.35 |
| D014456 | Ulcer NIH | 0.17 |
| D003092 | Colitis NIH | 0.17 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100280 | Crohn's disease HPO | 0.35 |
| HP:0002583 | Colitis HPO | 0.17 |
| HP:0100279 | Ulcerative colitis HPO | 0.17 |
Navigate: Correlations HPO
There are 3 clinical trials
The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active CD.
Description: The CDAI is used to evaluate disease activity in patients with Crohn's disease.
Measure: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission Time: Week 12Description: Endoscopic response defined as decrease from Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD).
Measure: Percentage of Participants With Endoscopic Response Time: Week 12Description: Clinical remission per average daily SF and average daily AP score.
Measure: Percentage of Participants With Clinical Remission Time: Up to Week 12Description: The CDAI is used to evaluate disease activity in patients with Crohn's disease.
Measure: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response Time: Up to Week 12Description: The FACIT-Fatigue is a validated tool that measures an individual's level of fatigue during their usual daily activities.
Measure: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Time: Week 12Description: The CDAI is used to evaluate disease activity in patients with Crohn's disease.
Measure: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission Time: Week 4Description: The CDAI is used to evaluate disease activity in patients with Crohn's disease. Endoscopic response defined as decrease from Baseline in SES-CD.
Measure: Percentage of Participants With CDAI Clinical Response and Endoscopic Response Time: Week 12Description: SF remission is defined using the average daily SF, and not worse than baseline.
Measure: Percentage of Participants With Stool Frequency (SF) Remission Time: Week 12Description: AP remission is defined using the average daily AP score, and not worse than baseline.
Measure: Percentage of Participants With Abdominal Pain (AP) Remission Time: Week 12Description: Endoscopic remission is defined as decrease in SES-CD as compared to baseline
Measure: Percentage of Participants With Endoscopic Remission Time: Week 12Description: Enhanced clinical response defined as decrease in average daily SF and/or decrease in average daily AP score, and/or clinical remission per average daily SF and average daily AP score.
Measure: Percentage of Participants With Enhanced Clinical Response Time: Up to Week 12Description: Endoscopic healing was assessed using SES-CD.
Measure: Percentage of Participants With Ulcer-Free Endoscopy Time: Week 12Description: Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.
Measure: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline Time: Week 12Description: Participants with an event that results in admission to the hospital.
Measure: Percentage of Participants With CD-Related Hospitalization Time: Up to Week 12Description: Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.
Measure: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline Time: Week 12The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).
Description: The CDAI is used to evaluate disease activity in patients with Crohn's disease.
Measure: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission Time: Week 12Description: Endoscopic response defined as decrease from Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD).
Measure: Percentage of Participants With Endoscopic Response Time: Week 12Description: Clinical remission per average daily stool frequency (SF) and average daily abdominal pain (AP) score.
Measure: Percentage of Participants With Clinical Remission Time: Week 12Description: The CDAI is used to evaluate disease activity in patients with Crohn's disease.
Measure: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response Time: Up to Week 12Description: The FACIT-Fatigue is a validated tool that measures an individual's level of fatigue during their usual daily activities.
Measure: Change From Baseline of Induction in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Time: Week 12Description: The CDAI is used to evaluate disease activity in patients with Crohn's disease.
Measure: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission Time: Week 4Description: The CDAI is used to evaluate disease activity in patients with Crohn's disease. Endoscopic response defined as decrease from Baseline in SES-CD.
Measure: Percentage of Participants With CDAI Clinical Response and Endoscopic Response Time: Week 12Description: SF remission is defined using the average daily SF, and not worse than baseline.
Measure: Percentage of Participants With Stool Frequency (SF) Remission Time: Week 12Description: AP remission is defined using the average daily AP, and not worse than baseline.
Measure: Percentage of Participants With Abdominal Pain (AP) Remission Time: Week 12Description: Endoscopic remission is defined as decrease in SES-CD as compared to baseline
Measure: Percentage of Participants With Endoscopic Remission Time: Week 12Description: Enhanced clinical response defined as decrease in average daily SF and/or decrease in average daily AP score, and/or clinical remission per average daily SF and average daily AP score.
Measure: Percentage of Participants With Enhanced Clinical Response Time: Up to Week 12Description: Endoscopic healing was assessed using SES-CD.
Measure: Percentage of Participants With Ulcer-Free Endoscopy Time: Week 12Description: Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.
Measure: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline Time: Week 12Description: Participants with an event that results in admission to the hospital.
Measure: Percentage of Participants With CD-Related Hospitalization Time: Up to Week 12Description: Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.
Measure: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline Time: Week 12The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2. The objective of Sub-Study 2 is to evaluate the efficacy and safety of risankizumab compared to placebo in inducing clinical remission in subjects with moderately to severely active UC.
Description: Clinical remission per adapted Mayo Score.
Measure: Sub-Study 1 and Sub-Study 2: Percentage of Participants with Clinical Remission per Adapted Mayo Score Time: Week 12Description: Endoscopic improvement per endoscopy subscore.
Measure: Sub-Study 1: Percentage of Participants with Endoscopic Improvement Time: Week 12Description: Clinical remission per Full Mayo Score.
Measure: Sub-Study 1: Percentage of Participants Achieving Clinical Remission per Full Mayo Score in Participants with a Full Mayo Score of 6 to 12 at Baseline Time: Week 12Description: Clinical response per adapted Mayo Score.
Measure: Sub-Study 1: Percentage of Participants Achieving Clinical Response per Adapted Mayo Score Time: Week 12Description: Week 4
Measure: Sub-Study 1: Percentage of Participants Achieving Clinical Response per Partial Adapted Mayo Score Time: Clinical response per Partial Adapted Mayo Score (without endoscopy).Description: Endoscopic remission per endoscopy subscore.
Measure: Sub-Study 1: Percentage of Participants with Endoscopic Remission Time: Week 12Description: Participants with an event that results in admission to the hospital.
Measure: Sub-Study 1: Percentage of Participants with Hospitalization Time: Through Week 12Description: Mucosal healing defined as endoscopic and histologic remission.
Measure: Sub-Study 1: Percentage of Participants with Mucosal Healing Time: Week 12Description: The US-SQ is a patient questionnaire to assess severity of Crohn's symptoms.
Measure: Sub-Study 1: Change in Ulcerative Colitis Symptom Questionnaire (UC-SQ) Time: Baseline Through Week 12Description: The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease.
Measure: Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Time: Baseline Through Week 12Description: The SF-36 is an indicator of overall health status.
Measure: Sub-Study 1: Change in Short Form-36 (SF-36) Time: Baseline Through Week 12Description: The FACIT-Fatigue is a validated tool that measures an individual's level of fatigue during their usual daily activities over the past week.
Measure: Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Time: Baseline Through Week 12Description: Participants who underwent surgery related to UC.
Measure: Sub-Study 1: Percentage of Participants with Ulcerative Colitis (UC)-related Surgeries Time: Through 12 weeksDescription: Clinical remission per Full Mayo Score.
Measure: Sub-Study 2: Percentage of Participants Achieving Clinical Remission per Full Mayo Score in Participants with a Full Mayo Score of 6 to 12 at Baseline Time: Week 12Description: Clinical response per adapted Mayo Score.
Measure: Sub-Study 2: Percentage of Participants Achieving Clinical Response per Adapted Mayo Score Time: Week 12Description: Percentage of participants who reported no abdominal pain.
Measure: Sub-Study 2: Percentage of Participants who Reported No Abdominal Pain Time: Week 12Description: Percentage of participants who reported no bowel urgency.
Measure: Sub-Study 2: Percentage of Participants who Reported No Bowel Urgency Time: Week 12Description: Endoscopic remission per endoscopy subscore.
Measure: Sub-Study 2: Percentage of Participants with Endoscopic Remission Time: Week 12Description: Endoscopic improvement per endoscopy subscore.
Measure: Sub-Study 2: Percentage of Participants with Endoscopic Improvement Time: Week 12Description: The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease.
Measure: Sub-Study 2: Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Time: Baseline Through Week 12Description: The FACIT-Fatigue is a validated tool that measures an individual's level of fatigue during their usual daily activities over the past week.
Measure: Sub-Study 2: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Time: Baseline Through Week 12Description: Percentage of participants with histological endoscopic improvement of the mucosa.
Measure: Sub-Study 2: Percentage of Participants with Histological Endoscopic Improvement of the Mucosa Time: Week 12Description: Percentage of participants who reported no nocturnal bowel movements.
Measure: Sub-Study 2: Percentage of Participants who Reported No Nocturnal Bowel Movements Time: Week 12Description: Percentage of participants who reported no tenesmus.
Measure: Sub-Study 2: Percentage of Participants who Reported No Tenesmus Time: Week 12Description: Change in number of fecal incontinence episodes per week.
Measure: Sub-Study 2: Change in Number of Fecal Incontinence Episodes per Week Time: Baseline Through Week 12Description: Change in number of days per week with sleep interrupted due to UC symptoms.
Measure: Sub-Study 2: Change in Number of Days per Week with Sleep Interrupted due to UC Symptoms Time: Baseline Through Week 12Description: Clinical response per partial adapted Mayo Score (without endoscopy), in participants with pancolitis at Baseline.
Measure: Sub-Study 2: Percentage of Participants Achieving Clinical Response per Partial Adapted Mayo Score in Participants with Pancolitis at Baseline Time: Week 12Description: Participants with an UC-related event that results in admission to the hospital.
Measure: Sub-Study 2: Percentage of Participants with Ulcerative Colitis (UC)-related Hospitalization Time: Through Week 12Description: The SF-36 is an indicator of overall health status.
Measure: Sub-Study 2: Change in Short Form-36 (SF-36) Time: Baseline Through Week 12Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports